$MLSS

Milestone Scientific (MLSS) reported Q2 2026 revenue of $2.8 million, up 22% year over year, and $5.0 million for the first six months, up 10%. CompuFlo medical revenue rose 230% and the company entered a distribution agreement with Red One Medical for VA and DoD systems. It reaffirmed 2026 double-digit revenue growth outlook.

MILESTONE SCIENTIFIC INC. (MLSS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000855683 0000855683 2026-07-27 2026-07-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Milestone Scientific Inc. (NYSE American: MLSS) said it launched the first phase of its AI strategy at ASPN 2026 in Miami Beach, debuting Milo, an AI-enabled digital engagement platform. The pilot will answer product questions, provide education, collect customer info, support lead qualification, and help schedule demos. The company plans to use attendee feedback to guide further development.

Milestone Scientific (NYSE: MLSS) reported preliminary, unaudited revenue for Q2 2026 of about $2.8M (+21% YoY) and 1H 2026 of about $5.0M (+9% YoY). The company expects medical-segment revenue up 300% YoY in Q2 and cites international order upside, plus reimbursement claims and conference plans in July.

MILESTONE SCIENTIFIC INC. (MLSS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.3 4 ex10-3.htm EX-10.3 Exhibit 10.3 As of June 19, 2026 Benedetta Casamento 346 Hillcrest Road Englewood, NJ 07631 Dear Benedetta: On behalf of the Board of Directors of Milestone Scientific Inc. (the “ Company ”), I am pleased to confirm your appointment as Executive Chair

Milestone Scientific (MLSS) reported a narrowed net loss of $0.84 million in Q1 2026, primarily due to sharply reduced operating expenses and a pause in R&D. Despite this improvement and positive operating cash flow, the company faces substantial doubt about its ability to continue as a going concern, evidenced by an accumulated deficit of $134.6 million and limited cash reserves. Additionally, MLSS remains below NYSE American listing thresholds, with a compliance deadline of April 2027, and its recent $2.15 million private placement introduced further dilution risks for existing shareholders.

Milestone Scientific Inc. (MLSS) has appointed Grassi & Co., CPAs, P.C. as its new independent registered public accounting firm, effective for the fiscal year ending December 31, 2026. This follows the dismissal of CBIZ CPAs P.C. as their auditor, a change approved by the company's Board of Directors. The previous auditor's report for 2025 indicated substantial doubt about Milestone Scientific's ability to continue as a going concern, though no disagreements on accounting principles or audit scope were reported.

Milestone Scientific Inc. ( NYSE:MLSS ) shares surged 35.67% in after-hours trading on Thursday, rising to $0.52. The medical device firm reported its third-quarter results showing lower costs and improved losses. Check out the current price of MLSS stock here.

ROSELAND, N.J., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- Milestone Scientific Inc. ( NYSE:MLSS ) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update highlighting the Company's transformation and growth ...

ROSELAND, N.J., Sept. 22, 2025 ( GLOBE NEWSWIRE ) -- Milestone Scientific Inc. MLSS, a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional ...